$OCGN next Target PT 70 and higher, long term PT 180 and higher
$OCGN " The Ocugen team has submitted a comprehensive drug master file with the FDA, and is currently diligently preparing the EUA application, according to Shankar Musunuri, Chairman of the Board, CEO and and co-founder of Ocugen."
$OCGN " The Ocugen team has submitted a comprehensive drug master file with the FDA, and is currently diligently preparing the EUA application, according to Shankar Musunuri, Chairman of the Board, CEO and and co-founder of Ocugen."